Linaclotide

Linaclotide is structurally modelled on heat-stable enterotoxins from E. coli and binds guanylate cyclase-C on the apical enterocyte membrane. The resulting rise in intracellular cGMP activates CFTR, driving chloride and bicarbonate into the lumen with water following osmotically — hence faster transit and softer stool. Crucially, some cGMP is exported extracellularly where it acts on submucosal afferent nerve endings, reducing firing of pain-sensing fibres. That second mechanism is why linaclotide relieves IBS-C abdominal pain rather than merely producing a bowel movement. Its three disulfide bonds make it rigid and protease-resistant enough to survive the gut, and it is essentially not absorbed — the active metabolite MM-419447 is formed locally in the lumen.

Targets: Guanylate cyclase-C (GC-C), CFTR chloride channel, cGMP-mediated afferent nociceptor modulation

• · 290 mcg is the only approved IBS-C dose. Swallow whole; do not chew or break the capsule.
• · 145 mcg is standard; 72 mcg is a lower-strength option for patients who need one, and is also the paediatric functional constipation dose for ages 6-17.

Work out your exact syringe units →

• very commonDiarrhoea— Around 20% of patients; the dose-limiting effect and the most common reason for discontinuation. Usually starts within the first two weeks.
• commonAbdominal pain and distension
• commonFlatulence
• uncommonSevere dehydration and electrolyte loss— Mainly a paediatric concern, and the basis of the boxed warning. Stop and rehydrate if diarrhoea becomes severe.

• Children under 2 years — boxed warning; fatal dehydration occurred in juvenile animal studies.
• Known or suspected mechanical gastrointestinal obstruction.

• redundantplecanatide — Same guanylate cyclase-C target; using both only stacks diarrhoea risk.
• cautionosmotic-laxatives — Additive with PEG, magnesium and lactulose — expect more diarrhoea and electrolyte loss.
• cautiondiuretics — Compounding fluid and electrolyte losses if diarrhoea develops.

• · Stool frequency and consistency using the Bristol scale — the practical way to decide whether to drop a dose strength.
• · Electrolytes if diarrhoea is persistent or severe.
• · In IBS-C, reassess abdominal pain at 12 weeks; if there is no pain benefit by then, the drug is unlikely to deliver one.

FDA-approved (Linzess) and EMA-approved (Constella). Prescription-only.

• Linzess (linaclotide) US prescribing information, AbbVie/Ironwood (label)
• Chey et al. 2012, linaclotide phase 3 in IBS-C, American Journal of Gastroenterology (trial)
• Lembo et al. 2011, linaclotide phase 3 in chronic constipation, NEJM (trial)

Linaclotide has two mechanisms, and only one of them is about bowel movements. Missing the second is the most common misunderstanding of this drug. The first is secretory. Binding guanylate cyclase-C on the apical enterocyte membrane activates the receptor's intracellular catalytic domain, raising intracellular cGMP. cGMP activates protein kinase G II, which phosphorylates and opens CFTR. Chloride and bicarbonate move into the lumen and water follows osmotically. More luminal water means softer stool and faster transit. This is the mechanism that produces a bowel movement, and it is also the mechanism that produces diarrhoea when it is overdone — the same axis that E. coli heat-stable enterotoxin exploits. The second is antinociceptive, and it is why linaclotide is a genuinely different drug from a laxative. Some of the cGMP generated inside the enterocyte is actively exported across the basolateral membrane into the submucosa, where it acts on the terminals of extrinsic primary afferent nociceptors. Extracellular cGMP reduces the firing of those pain-sensing fibres. In animal models of visceral hypersensitivity this effect is separable from the secretory effect and persists when transit is normalised. Clinically it is why abdominal pain improves in IBS-C rather than just stool frequency, and it is why the pain benefit takes 6-12 weeks to mature while the bowel effect appears in 24 hours. Those are two different mechanisms on two different timescales inside one capsule. The practical corollary: if you are taking linaclotide for IBS-C pain and you stop at week three because your bowels are fine, you have stopped before the part you actually wanted arrived. The food effect is worth understanding rather than just obeying. Taking linaclotide immediately after a high-fat breakfast produces looser and more frequent stools. That is because a fed stomach delivers the peptide to the small intestine differently — more of it arrives at once in a segment with more surface. The 30-minutes-before-food rule is not superstition, it is the difference between a formed stool and an urgent one.

The most common failure is taking it with food. The label says at least 30 minutes before the first meal, and people ignore it, then get watery stools and quit the drug. Fed administration measurably increases loose and frequent stools. This single instruction accounts for a large share of avoidable discontinuations. The second is quitting at week three because the pain has not improved. The bowel effect arrives in 24 hours; the visceral pain effect takes 6-12 weeks. People judge the drug on the wrong timescale for the thing they actually wanted. The third is not dropping a strength. Diarrhoea is dose-related, there are three strengths, and most of the benefit survives a step down from 290 to 145 mcg. Far too many people stop entirely instead of stepping down. The fourth is the pill organiser. Linaclotide is moisture-sensitive and the bottle contains a desiccant. Decanting a week's capsules into a plastic organiser degrades them. Keep them in the original bottle. The fifth is the boxed warning, which is real: contraindicated under 2 years of age, where juvenile animal studies showed fatal dehydration. This is not a theoretical paediatric caution. The sixth, and the one that matters most: using it to paper over an undiagnosed problem. Constipation with weight loss, bleeding, anaemia, a family history of colorectal cancer, or onset after age 50 needs investigation, not a GC-C agonist.

1. 290 mcgIBS-C, from day one — 290 mcg once daily, at least 30 minutes before the first meal of the day. This is the only approved IBS-C dose and there is no upward titration. Swallow the capsule whole.
2. 145 mcgChronic idiopathic constipation, from day one — 145 mcg once daily is the standard CIC dose, same timing. Note that CIC dosing is half the IBS-C dose — the extra 145 mcg in IBS-C is buying the visceral pain effect, not more stool.
3. 145 mcgIf diarrhoea is limiting, from week 2 — The real ladder on linaclotide is downward. Dropping from 290 to 145 mcg typically keeps most of the benefit while substantially reducing loose stools. Three available strengths is linaclotide's main practical advantage over plecanatide, which has one.
4. 72 mcgIf 145 mcg is still too much — 72 mcg once daily. This is also the paediatric functional constipation dose for ages 6-17. If you cannot swallow the capsule, it may be opened and sprinkled on applesauce or dispersed in water — but use it immediately.
5. —Week 12 — Reassess abdominal pain in IBS-C at 12 weeks. In the phase 3 trials the pain benefit accrued over that window. If there is no pain benefit by week 12, there will not be one, and you are taking an expensive laxative.

• Guanylate cyclase-C (GUCY2C), human — pKi 8.9 (approximately 1.3 nM) by competitive inhibition of [125I]-STa binding, per the IUPHAR/BPS Guide to Pharmacology. Rat pKi 8.4.

  Agonism at the apical enterocyte surface, activating the receptor's guanylate cyclase domain and raising intracellular cGMP. Unlike plecanatide, linaclotide's binding is not strongly pH-dependent, so it remains active throughout the small bowel and colon.

• CFTR chloride channel — Not a direct target.

  Opened downstream via cGMP and protein kinase G II, driving chloride and bicarbonate secretion with obligate water movement. This is the entire secretory and transit effect.

• Extrinsic primary afferent nociceptors (submucosal) — Acted on by exported extracellular cGMP rather than by linaclotide itself.

  Reduced firing of visceral pain fibres. This is the abdominal pain mechanism in IBS-C, it is separable from the secretory effect, and it matures over 6-12 weeks rather than 24 hours.

• MM-419447 (des-tyrosine linaclotide, active metabolite) — Full GC-C agonist; a specific affinity value was not resolved here.

  Formed in the gut lumen by loss of the terminal tyrosine and carries substantial pharmacological activity. It is the only active species recovered in faeces.

• Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial (Chey et al.) Phase 3 · n=804 · 26 weeks · 2012

  FDA composite responder: at least 30% improvement from baseline in average daily worst abdominal pain plus an increase of at least one complete spontaneous bowel movement, both in the same week, for at least 6 of 12 weeks. Result: 33.7% on linaclotide 290 mcg versus 13.9% on placebo. Pain improvement 48.9% versus 34.5%; CSBM improvement 47.6% versus 22.6%.

• Two randomized trials of linaclotide for chronic constipation (Lembo et al.) Phase 3 · n=1276 · 12 weeks · 2011

  Three or more complete spontaneous bowel movements per week plus an increase of at least one CSBM from baseline, during at least 9 of 12 weeks. For the 290 mcg dose: 19.4% (Trial 303) and 21.3% (Trial 01) versus 3.3% and 6.0% on placebo.

• Randomised clinical trials: linaclotide phase 3 studies in IBS-C, prespecified further analysis based on EMA-specified endpoints (Quigley et al.) Phase 3 (secondary analysis) · 2013

  Reanalysis of the phase 3 IBS-C programme against European Medicines Agency responder definitions, supporting the EU approval as Constella.

• Randomized trial of 2 delayed-release formulations of linaclotide in patients with IBS-C (Chey et al.) Phase 2 · 2021

  Comparison of delayed-release linaclotide formulations designed to deliver drug more distally, testing whether abdominal pain benefit can be separated from the diarrhoea liability.

A bowel movement often occurs within the first 24 hours, sometimes the first 6-8 hours, and the first few days can be more urgent than steady state. Stool frequency stabilises over 1-2 weeks. Abdominal pain relief in IBS-C builds gradually over 6-12 weeks — this is the slow mechanism, and it is the reason to reassess at week 12 rather than week 3. Stopping the drug returns constipation within days; there is no residual benefit and no withdrawal.

Do not combine linaclotide with plecanatide. Identical target, identical downstream mechanism, and you are just stacking diarrhoea risk. Pick one. Osmotic laxatives — PEG, magnesium, lactulose — are additive on both stool water and electrolyte loss. If you are adding linaclotide to an existing PEG regimen, cut the PEG first rather than layering. Diuretics are the interaction that actually sends people to hospital. Secretory diarrhoea plus a loop diuretic in an older adult produces hypokalaemia and prerenal failure faster than most people expect. If both are on board, have a written rule for when to hold the diuretic. The combination that works well in practice is linaclotide plus a soluble fibre and adequate fluid, which tends to produce a more formed stool than linaclotide alone. Timing matters more than the specific fibre. One useful pairing is with a low-FODMAP dietary trial in IBS-C. They address different components — linaclotide addresses transit and visceral pain, diet addresses fermentation and distension — and the combination often outperforms either.

Linaclotide versus plecanatide is the practical decision most people in this space actually face, and the honest summary is: similar efficacy, different side effect profile, different flexibility. Diarrhoea rates are the clearest difference. Linaclotide runs around 20% in IBS-C at 290 mcg and 16% in CIC at 145 mcg per its label; plecanatide runs around 4.3% in IBS-C and 5% in CIC at its single 3 mg strength. That is a real gap, though it comes from separate trial programmes rather than a head-to-head study, and there has never been an adequately powered direct comparison. Linaclotide's advantage is three strengths. If diarrhoea is limiting, you can step down and keep most of the benefit. Plecanatide has one strength and no fallback — your only option is to stop. Plecanatide's advantage is that it can be taken with or without food, at any time of day. Linaclotide's empty-stomach requirement is a genuine adherence tax. Against the rest of this class: linaclotide is one of only three genuinely orally active peptide drugs here with label-grade evidence, alongside plecanatide and, by a different route, teduglutide. Compared with BPC-157 or KPV for gut symptoms, this is not a comparison of degree — it is thousands of randomised patients versus rodent models.

A branded prescription product in the US (Linzess) and EU (Constella), with no generic at the time of writing. Cash price is high and insured cost is usually a modest copay, so the real number depends almost entirely on coverage. I did not verify a current price and will not quote one.

• ?No systemic PK parameters exist and none can be calculated, because plasma concentrations are below the assay limit. All PK numeric fields are null for that reason.
• ?The affinity of the active metabolite MM-419447 at guanylate cyclase-C was not resolved to a number.
• ?The 6-12 week timescale for abdominal pain benefit is drawn from the trial assessment windows rather than from a formal onset-of-effect analysis.
• ?Head-to-head comparative data against plecanatide do not exist; the diarrhoea rate comparison is cross-trial and should be read with that caveat.
• ?Cost figures are omitted rather than estimated, since US branded pricing varies enormously by payer and I did not verify a figure.
• ?The delayed-release formulation work is real and published, but whether any delayed-release linaclotide product will reach market is unresolved.

• Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety Chey WD, Lembo AJ, Lavins BJ, et al., The American Journal of Gastroenterology, 2012 · PMID 22986437

  The pivotal IBS-C trial. 804 patients, 26 weeks, 33.7% versus 13.9% on the FDA composite endpoint.

• Two randomized trials of linaclotide for chronic constipation Lembo AJ, Schneier HA, Shiff SJ, et al., The New England Journal of Medicine, 2011 · PMID 21830967

  The two pivotal chronic constipation trials, 1276 patients total, published in NEJM. This is as good as evidence gets in this class.

• LINZESS (linaclotide) capsules, US prescribing information Allergan / AbbVie, DailyMed / FDA label

  Source for the 14-residue sequence and 1526.8 Da weight, the below-limit-of-quantitation plasma data, the MM-419447 active metabolite, the 3-5% faecal recovery, the food effect, and the diarrhoea rates (20% at 290 mcg in IBS-C, 16% at 145 mcg in CIC, roughly 2% severe in each).

• Linaclotide, IUPHAR/BPS Guide to Pharmacology ligand 5017 — guanylyl cyclase-C pKi 8.9 (human), 8.4 (rat) IUPHAR/BPS Guide to Pharmacology

  Receptor affinity, determined by competitive inhibition of [125I]-STa binding.

• Randomised clinical trials: linaclotide phase 3 studies in IBS-C — a prespecified further analysis based on European Medicines Agency-specified endpoints Quigley EM, et al., Alimentary Pharmacology & Therapeutics, 2013 · PMID 23116208

  The EMA-endpoint reanalysis behind the European approval.

• Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation Chey WD, et al., The American Journal of Gastroenterology, 2021 · PMID 33065589

  The attempt to deliver linaclotide more distally and decouple the pain benefit from the diarrhoea. Relevant to anyone whose only problem with the drug is loose stools.